Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
Status:
Completed
Trial end date:
2016-08-19
Target enrollment:
Participant gender:
Summary
Study to assess the potential effects of lurbinectedin (PM01183) at a therapeutic dose on the
duration of the QTc interval, measured by electrocardiograms (ECGs), to characterize the
PM01183 plasma concentration/QTc relationship, and to explore related ECG parameters in
patients with selected solid tumors.